KBC Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

KBC Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$44K	Hold	2,941	–	–	﹤0.01%	1750
2026 Q2	$98K	Hold	2,941	–	–	﹤0.01%	1436
2026 Q1	$62K	Hold	2,941	–	–	﹤0.01%	1576
2025 Q4	$68K	Hold	2,941	–	–	﹤0.01%	1511
2025 Q3	$88K	Hold	2,941	–	–	﹤0.01%	1342
2025 Q2	$107K	Sell	2,941 -755	-20%	-$27.2K	﹤0.01%	1161
2025 Q1	$134K	Sell	3,696 -57,314	-94%	-$2.38M	﹤0.01%	1313
2024 Q4	$2.57M	Buy	61,010 +58,442	+2,276%	+$2.9M	0.01%	648
2024 Q3	$143K	Buy	2,568 +506	+25%	+$25.8K	﹤0.01%	1083
2024 Q2	$85K	Buy	2,062 +478	+30%	+$20.4K	﹤0.01%	1266
2024 Q1	$74K	Hold	1,584	–	–	﹤0.01%	1300
2023 Q4	$76K	Hold	1,584	–	–	﹤0.01%	1237
2023 Q3	$56K	Buy	+1,584	New	+$62.8K	﹤0.01%	1354

Other funds holding RARE

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Crestwood Advisors Group Boston, Massachusetts $6.76B AUM 24% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return

L. Roy Papp & Associates Phoenix, Arizona $981M AUM 26.21% 1-Year Est. Return

Motley Fool Asset Management Alexandria, Virginia $2.64B AUM 26.58% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return

KBC Group's RARE Position: Q3 2026 in Review

KBC Group held its Ultragenyx Pharmaceutical (RARE) position steady in Q3 2026 at 2,941 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

KBC Group first reported a position in RARE in Q3 2023 and has held it in 13 quarters since. The position peaked at $2.57M in Q4 2024. 48 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

KBC Group held 2,941 shares of Ultragenyx Pharmaceutical worth $44K as of Q3 2026.
KBC Group left its Ultragenyx Pharmaceutical share count unchanged in Q3 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1750 holding.
KBC Group first reported a position in Ultragenyx Pharmaceutical in Q3 2023 and has held it in 13 quarters since.
KBC Group's Ultragenyx Pharmaceutical position peaked at $2.57M in Q4 2024.
48 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.